NO20005042L - FremgangsmÕter for Õ inhibere MRP1 - Google Patents

FremgangsmÕter for Õ inhibere MRP1

Info

Publication number
NO20005042L
NO20005042L NO20005042A NO20005042A NO20005042L NO 20005042 L NO20005042 L NO 20005042L NO 20005042 A NO20005042 A NO 20005042A NO 20005042 A NO20005042 A NO 20005042A NO 20005042 L NO20005042 L NO 20005042L
Authority
NO
Norway
Prior art keywords
methods
mrp1
inhibit
inhibit mrp1
totally
Prior art date
Application number
NO20005042A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005042D0 (no
Inventor
Joseph Michael Gruber
Bryan Hurst Norman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20005042D0 publication Critical patent/NO20005042D0/no
Publication of NO20005042L publication Critical patent/NO20005042L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20005042A 1998-04-08 2000-10-06 FremgangsmÕter for Õ inhibere MRP1 NO20005042L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8107798P 1998-04-08 1998-04-08
PCT/US1999/007343 WO1999051227A1 (fr) 1998-04-08 1999-04-07 Procedes d'inhibition de mrp1

Publications (2)

Publication Number Publication Date
NO20005042D0 NO20005042D0 (no) 2000-10-06
NO20005042L true NO20005042L (no) 2000-10-06

Family

ID=22161958

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005042A NO20005042L (no) 1998-04-08 2000-10-06 FremgangsmÕter for Õ inhibere MRP1

Country Status (17)

Country Link
US (1) US6417193B1 (fr)
EP (1) EP1069897A1 (fr)
JP (1) JP2002510624A (fr)
KR (1) KR20010042482A (fr)
CN (1) CN1296408A (fr)
AU (1) AU3468099A (fr)
BR (1) BR9909497A (fr)
CA (1) CA2327706A1 (fr)
EA (1) EA200001036A1 (fr)
HU (1) HUP0101736A3 (fr)
ID (1) ID27048A (fr)
IL (1) IL138391A0 (fr)
NO (1) NO20005042L (fr)
PL (1) PL343312A1 (fr)
SK (1) SK15002000A3 (fr)
TR (1) TR200002803T2 (fr)
WO (1) WO1999051227A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2251901A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Methods and compounds for inhibiting MRP1
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
WO2001096346A1 (fr) 2000-06-14 2001-12-20 Eli Lilly And Company Composes tricycliques utilises comme inhibiteurs de mrp1
AU2001268040A1 (en) 2000-06-23 2002-01-08 Eli Lilly And Company Methods and compounds for inhibiting mrp1
AU2001294518A1 (en) * 2000-09-22 2002-04-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
ATE311392T1 (de) 2001-04-09 2005-12-15 Lilly Co Eli Verbindungen und methoden zur inhibierung von mrp1
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
CN104002843A (zh) * 2014-05-29 2014-08-27 安徽银龙泵阀股份有限公司 一种减震效果好易于放置的双泵移动车

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity

Also Published As

Publication number Publication date
HUP0101736A2 (hu) 2001-11-28
TR200002803T2 (tr) 2000-12-21
NO20005042D0 (no) 2000-10-06
CA2327706A1 (fr) 1999-10-14
SK15002000A3 (sk) 2001-06-11
WO1999051227A1 (fr) 1999-10-14
BR9909497A (pt) 2000-12-12
CN1296408A (zh) 2001-05-23
JP2002510624A (ja) 2002-04-09
ID27048A (id) 2001-02-22
EA200001036A1 (ru) 2001-04-23
KR20010042482A (ko) 2001-05-25
IL138391A0 (en) 2001-10-31
PL343312A1 (en) 2001-08-13
US6417193B1 (en) 2002-07-09
EP1069897A1 (fr) 2001-01-24
AU3468099A (en) 1999-10-25
HUP0101736A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
EP0785927A4 (fr) Nouveaux benzoxazoles
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
DE60141339D1 (de) Oximderivate und ihre verwendung als latente saüre
NO20000325L (no) Absorbentsammensetning for rensing av gasser som inneholder sure komponenter
DE60112933D1 (de) N-phenyl-4-(4-pyridyl)-2-pyrimidinamine-derivate
BR0313686A (pt) Compostos quìmicos
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
NO20032283L (no) Belegg for å hindre erosjon av brönnhullskomponenter
NO20005042L (no) FremgangsmÕter for Õ inhibere MRP1
DE69918465D1 (de) Sulfonamidhydroxamate
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
NO20005041L (no) FremgangsmÕte for Õ inhibere MRP1
NO20005023L (no) Fremgangsmåter for å hemme MRP1
DK1021421T3 (da) Amino- og hydroxy-substituerede triphenyl-S-triaziner som stabilisatorer
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AR021114A1 (es) Procedimiento de fotoestabilizacion de filtros solares derivados de 1,3,5-triazina
WO2002024690A8 (fr) Procede de preparation efficace d'un inhibiteur du facteur xa
DE60222459D1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamide als factor xa inhibitoren
BRPI0409431A (pt) composto bicìclico, uso do mesmo, e, composição e método para controlar fungos fitopatogênicos
ATE310111T1 (de) Verwendung von organischen karbonaten als lösungsmittel zur reinigung von metalloberflächen
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
DK1192191T3 (da) Fremgangsmåde til fremstilling af kondensationsforbindelser
ECSP982576A (es) Derivados de epotilona

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application